Caring for Patients in Today's Opioid Landscape

In 2021, overdose deaths in the United States reached a record high. At the same time, restrictions on prescription opioids strand many patients without adequate care. For policymakers and providers, ensuring quality patient care and reducing harm requires navigating an evolving landscape of restrictions and best practices. The New York State Department of Health Commissioner’s Grand Round will convene subject-matter experts to discuss New York State’s response to the opioid crisis and harm reduction strategies; the importance of using a health equity lens in the treatment of opioid use disorder (OUD); and guidance for treating chronic pain with opioids.

How to watch this webcast

Session details:

Moderator

  • Mary T. Bassett, MD, MPH, Commissioner of the New York State Department of Health

Opening Remarks

  • Mary P. Gallant, PhD, MPH, Interim Dean, University at Albany School of Public Health

Speakers

  • Chinazo Cunningham, MD, MS, Commissioner, New York Office of Addiction Services and Supports
    Presentation (PDF)
  • Ayana Jordan, MD, PhD, Associate Professor, NYU Grossman School of Medicine Department of Psychiatry and Department of Population Health
    Presentation (PDF)
  • Joanna Starrels, MD, MS, Professor of Medicine, Psychiatry & Behavioral Science, Albert Einstein College of Medicine and Montefiore Medical Center Associate Chief of the Division of General Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center
    Presentation (PDF)

Continuing Education Credits

  • CME credit availability has expired for this session.

Disclosure Statements

Joanna L. Starrels, MD, MS has disclosed she is a site PI for an FDA-mandated, multi-site observational study of the risks of prescription opioids, through a sub-contract with the Clinical Directors' Network and the Opioid Post-marketing Requirement Consortium.

All relevant financial relationships have been mitigated.

None of the other planners, moderator, and presenters have any financial arrangements or affiliations with any ineligible companies whose products, research or services may be discussed in this activity.

No commercial funding has been accepted for this activity.